NCT02862210View on ClinicalTrials.gov

Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 27, 2017

Primary Completion Date

November 20, 2022

Study Completion Date

November 20, 2022

Conditions
Frontotemporal Dementia (FTD)
Interventions
DRUG

Lithium Carbonate

Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.

DRUG

Placebo

Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

Alzheimer's Drug Discovery Foundation

OTHER

lead

Columbia University

OTHER

NCT02862210 - Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia | Biotech Hunter | Biotech Hunter